Segment Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	2
Segment Reporting Information [Line Items]
Total Revenue	$ 137,220	$ 117,169
Total cost of revenue	82,406	78,937
GROSS PROFIT	54,814	38,232
General and administrative	61,549	66,248
Research and development	7,395	7,713
Sales and marketing	16,259	16,299
Restructuring charges	4,684	0
Total operating expenses	89,887	90,260
LOSS FROM OPERATIONS	(35,073)	(52,028)
Interest (income) expense, net	(1,467)	1,301
Other (income) expense, net	114	(168)
Loss before taxes	(33,720)	(53,161)
Income tax benefit	(2,925)	(3,753)
NET LOSS	(30,795)	(49,408)
Clinical Services
Segment Reporting Information [Line Items]
Total Revenue	114,869	98,791
Total cost of revenue	67,292	65,267
GROSS PROFIT	47,577	33,524
Amortization of acquired intangible assets	4,300	4,300
Pharma Services
Segment Reporting Information [Line Items]
Total Revenue	22,351	18,378
Total cost of revenue	15,114	13,670
GROSS PROFIT	7,237	4,708
Amortization of acquired intangible assets	$ 600	$ 600